Martijn van de Bunt
Chief Scientific Officer Cytoki Pharma
Dr. Martijn Van de Bunt is a distinguished physician-scientist and biopharmaceutical leader currently serving as Chief Scientific Officer of Cytoki Pharma, where he oversees scientific strategy to advance novel therapeutic development. With a unique dual background as both a medical doctor (MD, University of Amsterdam) and PhD researcher (University of Oxford), he brings exceptional translational perspective to drug discovery.
His extensive industry experience includes key roles at Novo Nordisk, most recently as Project Director for Real World Data & Science, where he led innovative evidence-generation initiatives, and earlier as a consultant driving strategic R&D decisions. Dr. Van de Bunt’s academic credentials are equally impressive, having served as a Junior Research Fellow at the University of Oxford’s Centre for Personalised Medicine and as a Novo Nordisk Postdoctoral Fellow, building on his doctoral research at Oxford.
A recognized expert at the intersection of clinical insight and research innovation, Dr. Van de Bunt specializes in translating complex scientific concepts into therapeutic solutions, with expertise in real-world data applications and personalized medicine approaches. His cross-disciplinary experience spanning academic research, pharmaceutical development, and clinical medicine makes him a compelling voice on the future of targeted therapies.
Seminars
- Targeting inflammation to restore metabolic homeostasis and leverage dual action therapies for metabolic restoration and reduction in chronic inflammation
- Promoting adipose browning and lean mass retention through RNA-Based miR-22 inhibition for fat remodelling and improved body composition
- Explore how CK-0045, a first-in-class IL-22 agonist being investigated in a Phase 2a study, offers a unique approach to obesity treatment through a novel non-incretin-based mode-of-action in the gut which preserves muscle mass during weight loss
- Understand the potential of CK-0045 to be used as a standalone therapy or in combination with current standard treatments, offering a broader spectrum of benefits that address both weight loss and deeper metabolic improvements
